HC Wainwright Lowers Earnings Estimates for Microbot Medical

Microbot Medical Inc. (NASDAQ:MBOT) – Equities research analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for shares of Microbot Medical in a research report issued on Wednesday, August 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.06). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Microbot Medical’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.28) EPS.

A number of other brokerages also recently weighed in on MBOT. Weiss Ratings reissued a “sell (d-)” rating on shares of Microbot Medical in a report on Wednesday, July 8th. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Loop Capital set a $4.00 price objective on shares of Microbot Medical in a research report on Wednesday, June 3rd. B. Riley Financial reiterated a “buy” rating and issued a $4.00 target price (down from $5.00) on shares of Microbot Medical in a research note on Friday, August 14th. Finally, Zacks Research raised Microbot Medical from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Microbot Medical currently has a consensus rating of “Moderate Buy” and an average price target of $6.38.

Microbot Medical Trading Down 3.9%

MBOT opened at $1.49 on Friday. Microbot Medical has a 1-year low of $1.44 and a 1-year high of $4.67. The stock has a market capitalization of $100.08 million, a price-to-earnings ratio of -6.21 and a beta of 1.06. The business has a 50 day moving average of $1.79 and a 200-day moving average of $2.05.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million.

Hedge Funds Weigh In On Microbot Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Bancorp USA Inc. acquired a new position in Microbot Medical in the third quarter worth about $4,435,000. DNB Asset Management AS boosted its holdings in Microbot Medical by 178.1% during the fourth quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock valued at $1,355,000 after purchasing an additional 433,869 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Microbot Medical by 14.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock valued at $7,148,000 after purchasing an additional 292,923 shares during the period. Geode Capital Management LLC raised its holdings in shares of Microbot Medical by 54.4% in the 4th quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 268,609 shares in the last quarter. Finally, 683 Capital Management LLC bought a new position in shares of Microbot Medical during the 4th quarter worth approximately $512,000. 16.30% of the stock is owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.